Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Introduction Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated P...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/5/6/e000942.full |